$LFWD

Lifeward Ltd. (LFWD) published a study showing its ReWalk exoskeleton improves daily activities, satisfaction, and reduces pain for spinal cord injury patients. All 12 participants performed kitchen activities, 10 did grooming. ReWalk sales rose 13% YoY to $2.5M in Q2 2026, with total LFWD revenue up 16% to $6.6M. LFWD stock is currently at $7.11, down 0.14%.

Oramed Pharmaceuticals (ORMP) has entered a milestone-based funding deal with Lifeward (LFWD), a maker of exoskeleton devices. Lifeward highlighted its strategic partnership with Oramed in an investor presentation, noting potential benefits and funding availability. The company aims to leverage robotics, AI, and reimbursement to grow in the rehabilitation market, with projections of significant market expansion by 2030.

Lifeward Ltd. (LFWD) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 NASDAQ: LFWD Platform to Restore Motion, Dignity, and Independence Transforming Rehabilitation. Changing Lives. Investor Presentation · September 2026 Forward - Looking Statements This presentation contains forward - looking statements within the meaning of Section 2

Lifeward Ltd. (LFWD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of President and Chief Executive Officer Effective August 31, 2026, Mr. Mark Grant will depart from his positions

Lifeward Ltd. (LFWD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer. Appointment of Directors On August 14, 2026, the Board of Directors (the “Board”) of Lifeward Ltd. (the “Company”) appointed

Lifeward Ltd. (Nasdaq: LFWD) reported Q2 2026 revenue up 16% to $6.6 million from $5.7 million a year earlier, driven by ReWalk sales rising 13% to $2.5 million and AlterG products and services up 25% to $4.1 million. Gross margin was 41%. Net loss was $11.5 million ($4.12/share). The company said it raised about $5.6 million in July financing and launched a pilot with Ottobock Care.

Lifeward Ltd. (LFWD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lifeward Reports Strong Second Quarter 2026 Financial Results as Commercial Execution Drives Growth Revenue increase and operating performance improve as capital-efficient distribution strategy gains momentum Strengthened balance sheet and expanding rehabilitation pl

Lifeward Ltd. (NASDAQ: LFWD) said it will release its Q2 2026 financial results on Friday, Aug. 14, via a press release and an SEC quarterly report filed before 9:30 a.m. ET. The company highlighted its neurorehabilitation products and its Protein Oral Delivery platform, including ORMD-0801 oral insulin.

Lifeward Ltd. (Nasdaq: LFWD) said it entered a securities purchase agreement for strategic financing with institutional investors. The initial July 6 closing provides about $5.6M in senior secured convertible notes and warrants, with up to another $5.6M tied to milestones: 150% ReWalk unit sales growth or shares at/above $13.80 for 10 days.

Lifeward Ltd. (LFWD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 7 exhibit_10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June 30, 2026, among Lifeward Ltd., a company organized under the laws of the State of Israel (the “ Company ”), each purchase